Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00876031 | Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma | PHASE3 | COMPLETED | 195 | — | — | Jul 1, 2009 | Jun 30, 2022 | Nov 8, 2022 | 87 | Austria, Germany +3 |
| Arm | Type | Description |
|---|---|---|
| O-TIE | EXPERIMENTAL | oral maintenance therapy with trofosfamide, idarubicin, and etoposide |
| control | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| trofosfamide, idarubicin, etoposide | DRUG | oral maintenance therapy for 6 months |
Inclusion Criteria: * written informed consent for registration, randomisation, data collection/transfer, and tumour material asservation available * pathologically (including molecular pathology) proven diagnosis of rhabdomyosarcoma (RMS) or RMS-like soft tissue sarcoma (STS) and tumour material a...